The RAF-MEK-ERK pathway regulates both myoblast proliferation and differentiation; however, it is unclear how these events are coordinated. Here, we show that human phosphatidylethanolamine-binding protein 4 (PEBP4), a RAF kinase inhibitory protein (RKIP) family protein expressed preferentially in muscle, regulates the activity of the ERK pathway and myoblast differentiation by acting as a scaffold protein. In contrast to RKIP, which disrupts the RAF1-MEK interaction, PEBP4 forms ternary complexes with RAF1 and MEK, and can scaffold this interaction. PEBP4 expression is induced during the differentiation of primary human myoblasts. Consistent with the properties of a scaffold, PEBP4 enhances the RAF1-MEK interaction and the activation of MEK at low expression levels, whereas it inhibits these parameters at higher expression levels. Downregulation of PEBP4 by short hairpin RNA in human myoblasts increases MEK signalling and inhibits differentiation; by contrast, PEBP4 overexpression enhances differentiation. Thus, PEBP4 participates in the control of muscle cell differentiation by modulating the activity of MEK and ERK.
INTRODUCTION
The RAF-MEK-ERK pathway participates in the regulation of many biological processes, including proliferation and differentiation. It has a crucial function in muscle cell differentiation, although both negative (Rommel et al, 1999; Yang et al, 2006; Yokoyama et al, 2007) and positive effects have been reported (Gredinger et al, 1998; Li & Johnson, 2006; Cho et al, 2007) . These discrepant observations are not necessarily mutually exclusive as, in other cell systems, for example, cancer cell line PC12, the activation kinetics of the pathway is crucial, with transient activation mediating proliferation and sustained activation inducing neuronal differentiation (Marshall, 1995) .
Increasing evidence shows that ERK signalling is modulated by proteins that regulate the interaction between pathway components (Kolch, 2005) . Negative regulators include the RAF kinase inhibitory protein (RKIP; Yeung et al, 1999) . RKIP inhibits the phosphorylation and activation of MEK by RAF1 by disrupting its interaction (Yeung et al, 1999) . Recently, a new member of the RKIP family, human phosphatidylethanolamine-binding protein 4 (PEBP4), was described (Wang et al, 2004) ; PEBP4 expression was reported in human cancer cells. Tumour necrosis factor-a (TNFa) stimulated PEBP4 expression, its translocation from lysosomes to the cell membrane, and its association with RAF1 and MEK. Overexpression of PEBP4 in L929 fibroblasts inhibited TNFainduced apoptosis, and the activation of ERK and JNK. Conversely, the downregulation of endogenous PEBP4 in human MCF7 breast cancer cells sensitized cells to TNFa-induced apoptosis and cellcycle arrest (Wang et al, 2004 (Wang et al, , 2005 . The reduction of endogenous PEBP4 expression in MCF7 cells augmented the levels of proapoptotic proteins such as p53, p21 CIP/WAF and BAX (BCL2-associated X protein), while reducing the levels of protective proteins such as BCL2 (B-cell CLL/lymphoma 2) and BCLX L (Wang et al, 2005) . Further investigations have shown that PEBP4 can protect CaoV-3 ovarian cancer cells against TRAIL (TNFa-related apoptosis inducing ligand)-induced apoptosis by limiting TRAIL-induced ERK and JNK activation . Similarly, in prostate cancer cell lines, PEBP4 expression correlated with sensitivity to TRAIL-induced apoptosis. TRAILsensitive DU145 prostate cancer cells lacked PEBP4, whereas TRAIL-resistant LNCaP cells showed high expression . Overexpressing PEBP4 in DU145 cells inhibited the activity of ERK but promoted AKT activation, which made the cells resistant to TRAIL-induced apoptosis. Downregulation of endogenous PEBP4 in LNCaP cells had the opposite effect. As PEBP4 expression was also elevated in advanced prostate cancer, PEBP4 might promote tumorigenesis by enhancing the survival capabilities of cancer cells. Recently, a mouse homologue of human PEBP4 was identified, which is specifically expressed in retinal ganglion cells and promotes cell migration and protects against drug-induced apoptosis . The sequence identity of mouse PEBP4 with human PEBP4 is only 44.6% on the protein level and, owing to the different pattern of expression, it is unclear whether the mouse and human homologues have similar functions.
As PEBP4 shares homology to RKIP and binds to RAF1 and MEK, it was surmised to act in a similar manner to RKIP (Wang et al, 2004) ; however, there are clear functional differences. First, PEBP4 protects cancer cells against apoptosis, whereas RKIP overexpression is associated with the enhancement of apoptosis (Chatterjee et al, 2004; Al-Mulla et al, 2006) and good prognosis (Fu et al, 2003; Schuierer et al, 2004; Hagan et al, 2005; Al-Mulla et al, 2006) . In addition, RKIP does not regulate the JNK pathway (Yeung et al, 1999) . These differences show that RKIP and PEBP4 are not functionally equivalent. Importantly, the molecular mechanism of PEBP4 action is not characterized. Here, we show that PEBP4 uses a different molecular mechanism to regulate ERK by acting as a scaffold. We also show a hitherto unknown role for PEBP4 in myoblast differentiation.
RESULTS AND DISCUSSION PEBP4 forms ternary complexes with RAF1 and MEK
We isolated PEBP4 as RKIP-related protein (supplementary Fig S1  online) . PEBP4 co-immunoprecipitated with RAF1 and MEK when exogenously expressed as tagged proteins (Fig 1A) . PEBP4 is Lysates from growing HSMM were immunoprecipitated with unrelated IgG or RAF1 C12 antibodies (directed against the carboxy-terminal 12 aa of RAF1) covalently crosslinked to beads. RAF1 protein was eluted from the beads by competition with the synthetic C12 peptide. The eluate was split into two aliquots that were immunoprecipitated with a polyclonal MEK1/2 antibody. The immunoprecipitates were blotted with antibodies against RAF1, MEK and PEBP4 as indicated. GST, glutathione S-transferase; HA, haemagglutinin; HSMM, human skeletal muscle myoblast; IgG, immunoglobulin G indicated with an asterisk; IP, immunoprecipitation; PEBP4, human phosphatidylethanolamine-binding protein 4; WB, Western blot.
Human PEBP4 in muscle differentiation R. Garcia et al mainly expressed in muscle tissues (supplementary Fig S2 online) . Thus, these interactions were verified by co-immunoprecipitation of endogenous proteins from primary SkMC human muscle cells. Endogenous PEBP4 co-immunoprecipitated with both endogenous RAF1 and MEK ( Fig 1B) . We examined whether PEBP4 can form ternary complexes with RAF1 and MEK by using a sequential immunoprecipitation procedure ( Fig 1C) . For this purpose, glutathione S-transferase (GST) or GST-RAF1 was transiently coexpressed with FLAG-PEBP4 and haemagglutinin (HA)-MEK. GST proteins were pulled down using glutathione sepharose beads and eluted with glutathione. Subsequently, the eluted proteins were immunoprecipitated with FLAG antibodies to isolate the proteins associated with FLAG-PEBP4. Both HA-MEK and GST-RAF1 were detected in the FLAG-PEBP4 precipitate, suggesting that PEBP4 can form ternary complexes with RAF1 and MEK, and might function as a scaffold protein for RAF1-MEK interactions. This sharply distinguishes it from RKIP, which disrupts the interaction between RAF1 and MEK (Yeung et al, 1999) , acting as a competitive inhibitor of MEK binding (Yeung et al, 2000) . Importantly, a ternary endogenous RAF1-MEK-PEBP4 complex also exists in muscle cells ( Fig 1D) and MCF7 cells (supplementary Fig S3 online) .
PEBP4 scaffolds RAF1-MEK interactions
Increasing PEBP4 expression in COS1 cells initially enhanced the binding of MEK to RAF1, but dissipated the complex at higher concentrations (Fig 2A) . Similarly, increasing PEBP4 expression first enhanced the activation of MEK, but became inhibitory at high levels ( Fig 2B) . Such behaviour is typical for scaffold proteins; they promote complex formation of client proteins until their expression levels exceed the concentrations of their clients resulting in sequestration, which functionally results in inhibition. Overexpression of PEBP4 in proliferating SkMC myoblasts, where PEBP4 levels are low (Fig 3A) , resulted in an initial enhancement of MEK activation followed by suppression typical for a scaffold (Fig 2C) . To test the scaffolding function of PEBP4 more directly, we incubated in vitro RAF1 immobilized on beads with soluble MEK and PEBP4 or RKIP (Fig 2D) . Low concentrations of PEBP4 promoted the RAF1-MEK complex, formation, whereas higher concentrations interfered with it; by contrast, RKIP only inhibited it. These results confirm that RKIP acts as an inhibitor of the RAF1-MEK interaction, whereas PEBP4 can scaffold.
PEBP4 regulates MEK-ERK signalling
Muscle differentiation is well studied in the mouse C2C12 myoblast cell line. There, the ERK pathway mediates not only myoblast proliferation and inhibits myoblast fusion (Rommel et al, 1999; Yang et al, 2006; Yokoyama et al, 2007) , but also has a positive role in muscle differentiation (Gredinger et al, 1998; Li & Johnson, 2006; Cho et al, 2007) . Therefore, we determined the expression of PEBP4 and activity of the ERK pathway during differentiation of primary human SkMC myoblasts. Differentiation induced PEBP4 expression both on the messenger RNA and protein levels, and a concomitant decrease in the activation of MEK (Fig 3A) . Importantly, differentiation also induced an increase in PEBP4 association with MEK at the expense of RAF1 binding Human PEBP4 in muscle differentiation R. Garcia et al correlating with a decrease in ERK activation (Fig 3B) . Although PEBP4 could scaffold the MEK-ERK interaction when overexpressed in COS1 cells (supplementary Fig S4 online) , we could not consistently detect ERK co-precipitating with MEK and PEBP4 in primary muscle cells, presumably because the endogenous interaction is at the detection limit of our antibodies. In summary, these results suggest that PEBP4 regulates ERK pathway activation during differentiation by modulating protein interactions within the pathway.
To test this hypothesis, we downregulated the expression of endogenous PEBP4 in SkMC myoblasts by short hairpin RNA (shRNA). Owing to the difficulties of transfecting primary human cells and stably downregulating protein expression over a prolonged period of time, we assayed ERK pathway activation at day 2 of differentiation. Although the exact time course of differentiation is dependent on the batch of cells and passage number, the effects of PEBP4 on RAF1-MEK complexes and the activation of MEK were consistently observed at day 2. Reduction of PEBP4 mRNA by shRNA caused a robust activation of ELKmediated transcription in a reporter gene assay (Fig 3C) . ELK is a direct ERK substrate involved in the suppression of myogenesis (Wang et al, 2004) . It is an appropriate indicator of ERK activity in SkMCs, as ELK activity is induced by both activated RAF1 and MEK, and inhibited by a selective MEK1/2 inhibitor (supplemen- Human PEBP4 in muscle differentiation R. Garcia et al
tary Fig S5 online) . In addition, these assays confirmed that PEBP4 modulates the ERK pathway upstream from MEK, as activated RAF1 but not activated MEK was susceptible to the inhibition of PEBP4 (supplementary Fig S5 online) . Downregulation of endogenous PEBP4 expression induced the activation of MEK and ERK on day 2 of differentiation ( Fig 3D) . These results indicate that PEBP4 modulates RAF1 activation of MEK and ERK, and hence might affect myoblast differentiation.
PEBP4 regulates human myoblast differentiation
Therefore, we assessed the effects of PEBP4 overexpression or downregulation on SkMC differentiation. As the transfection efficiency of SkMC is poor, we co-transfected a low level of DsRed mito expression plasmid to allow enrichment of transfected cells by fluorescence-activated cell sorting (FACS). Sorted cells were induced to differentiate and were examined for the formation of multinucleated myotubes and the expression of myosin heavy chains (MyHCs) as morphological and biochemical markers for terminal differentiation, respectively. PEBP4 shRNA reduced myotube formation and the expression of MyHC, whereas transfection with a PEBP4 expression plasmid augmented both parameters (Fig 4A) . PEBP4-transfected SkMC cells also increased the expression of the early muscle differentiation markers, myogenin and p21 CIP/WAF (Fig 4B) , supporting a role for PEBP4 (A) SkMC myoblasts were co-transfected with DsRed mito plasmid and pcDNA3-PEBP4, pSUPER-PEBP4 shRNA or the respective empty vectors as indicated. FACS-sorted cells were placed in a differentiation medium (DM) and examined 3 days later for myosin heavy chain (MyHC) expression (green) and myotube formation as markers for terminal differentiation. Nuclei were stained with DAPI (blue). Results shown are representative of three independent experiments with X4,000 nuclei counted per experiment. (B) SkMC myoblasts were co-transfected with vector or pcDNA3-PEBP4 and induced to differentiate. Lysates were blotted for the differentiation markers, myogenin and p21 CIP/WAF . Blots were quantified by laser densitometry (lower panel). Results are representative of three independent experiments. DAPI, 4,6-diamidino-2-phenylindole; FACS, fluorescence-activated cell sorting; PEBP4, human phosphatidylethanolamine-binding protein 4; shRNA, short hairpin RNA.
Human PEBP4 in muscle differentiation R. Garcia et al in myoblast differentiation. These results were fully corroborated in human skeletal muscle myoblasts (HSMMs), another primary human myoblast cell strain using MyHC expression as a marker for terminal differentiation (supplementary Fig S6 online) . PEBP4 overexpression also decreased DNA synthesis agreeing with a role in promoting differentiation (supplementary Fig S7 online) .
PEBP does not mediate AKT inhibition of ERK signalling
AKT can inhibit the ERK pathway in differentiated mouse C2C12 muscle cells (Rommel et al, 1999) , and the direct phosphorylation of RAF1 on the inhibitory Ser 259 site by AKT was suggested as a mechanism . As AKT could bind to RAF1 in differentiated C2C12 myotubes but not in myoblasts, it was plausible to suggest that myotubes express an adaptor protein that facilitates the interaction between AKT and RAF1 (Rommel et al, 1999) . As PEBP4 co-immunoprecipitated with transfected AKT and endogenous AKT, and the interaction increased during myoblast differentiation (supplementary Fig S8A online (Dhillon et al, 2002) , but surprisingly also when PEBP4 was co-transfected. Co-transfection of AKT had no effect on the phosphorylation of Ser 259, whereas treatment with LY294002 slightly increased it (supplementary Fig S8D online) . Similarly, phosphorylation of Ser 259 did not change when SkMC cells were induced to differentiate despite a robust activation of AKT (supplementary Fig S8E online) . In addition, PEBP4 did not affect AKT kinase activity (supplementary Fig S9 online) , suggesting that the role of PEBP4 in myoblast differentiation is not exerted through the direct regulation of AKT. These data suggest that (i) RAF1 inhibition by AKT is not mediated by the phosphorylation of Ser 259 and that (ii) PEBP4 is unlikely to represent the postulated adaptor protein that mediates RAF1 inhibition by AKT. As PEBP4 attenuates the inhibition of RAF1 by AKT, a function as a positive modulator of the RAF1-AKT cross-talk is more plausible. For example, PEBP4 could act as part of a control mechanism that fine-tunes RAF1 activity during myoblast differentiation and eventually facilitates recovery from AKT-mediated inhibition.
METHODS

Plasmids.
The complete open reading frame sequence of CORK1 was deduced from sequencing IMAGE clone 1840766 and deposited in GenBank, accession number AY730275. For consistency with existing nomenclature, the CORK1 constructs are called PEBP4 throughout. Cell culture and transfections. SkMC and HSMM primary human myoblasts were propagated as specified by the supplier (Clonetics, Lonza, Wokingham, UK). To induce differentiation, confluent cells were switched to DMEM þ 2% horse serum. COS1, MCF-7 and HEK293 cells were maintained in DMEM þ 10% FCS. Subconfluent cells were transfected by lipofection, and HSMM by nucleofection (Amaxa, Walkersville, MD, USA). Reporter gene assays. SkMCs were transfected with Gal-ELK plasmids, which contain a Gal4 DNA-binding domain fused to an ELK transactivation domain that is activated by ERK (Kortenjann et al, 1994) . The readout was performed by assessing the activity of a Gal4 promoter-driven luciferase reporter plasmid using the luciferase assay system I (Promega, Southampton, UK). Immunoprecipitations, immunoblotting and RAF kinase assays. Immunoprecipitations, immunoblotting and RAF kinase assays were performed as described previously (Dhillon et al, 2002) except that cells were lysed in immunoprecipitation buffer (50 mM Tris-HCl pH 7.5, 15 mM EGTA, 150 mM NaCl, 0.1% (w/v) Triton X-100, 1 mM phenylmethyl sulphonyl fluoride, 1 mM dithiothreitol, 10 mg/ml leupeptin and 10 mg/ml aprotinin). In vitro binding assays. FLAG-RAF1 was expressed in HEK293 and immobilized on anti-FLAG M2 agarose beads (Sigma, Dorset, UK). GST-MEK was prepared from Sf9 cells as described previously (Dhillon et al, 2002) . PEBP4 and RKIP were expressed as GST fusion products in Escherichia coli and purified using glutathione sepharose (GE Healthcare) and released from GST by thrombin cleavage. FLAG-RAF1 beads were incubated simultaneously with soluble GST-MEK and PEBP4 or RKIP for 1 h at 4 1C in immunoprecipitation buffer. Fluorescence-activated cell sorting and immunocytochemistry. Myoblasts were co-transfected with the plasmids of interest and DsRed mito (Clontech). DsRed-positive cells were isolated by using an FACS Vantage SE cell sorter, seeded on eight-chamber glass slides at high density overnight and switched to a differentiation medium. Cells were fixed with 2% formaldehyde, permeabilized with 0.1% Triton X-100 and stained with the indicated antibodies. RNA interference. The target region of shRNA corresponding to codons 27-34 of the PEBP4 sequence was cloned into pSUPER as described previously (Brummelkamp et al, 2002) . Supplementary information is available at EMBO reports online (http://www.emboreports.org)
